Figure 1 | Scientific Reports

Figure 1

From: Nasal microbiota clusters associate with inflammatory response, viral load, and symptom severity in experimental rhinovirus challenge

Figure 1

Study outline and sampling set-up. Subjects were enrolled from three separate cohorts to receive either Bl-04 (2 × 109 CFU/day) or placebo for 28 days prior to being challenged with an experimental rhinovirus. The participants continued investigational product intake for 4 days post-challenge. On study day (D) 0, subjects were inoculated with rhinovirus type A39 (FDA-BB-IND #12934) (100 TCID50, split between both nostrils). On D1–D5, participants returned to the study site for assessment of infection symptoms assessed by WURSS-21, collection of nasal lavage for inflammatory marker analyses, and quantitative rhinovirus culture. Volunteers returned a final time at D28 for collection of convalescent serum for antibody to rhinovirus type A39.

Back to article page